Key Takeaways

  • Kratom products available in the U.S. are often highly processed derivatives and isolates, significantly different from the traditional leaf used in Southeast Asia, leading to confusion and potential harm for consumers.
  • The effects of kratom vary dramatically with dosage and product form, ranging from stimulant-like at lower doses to opioid-like sedation at higher doses, and the U.S. market lacks clear distinctions between these forms.
  • While many kratom users in the U.S. seek energy, mood elevation, or pain relief, a significant concern exists regarding highly concentrated or synthetically derived kratom products that act as pure opioids and pose substantial risks.
  • Kratom’s complex alkaloid profile, particularly 7-hydroxymitragynine, interacts with multiple systems, making it distinct from pure opioids and necessitating careful differentiation between leaf products and isolates.
  • The development and sale of synthetically derived kratom isolates, like 7-hydroxymitragynine, pose significant public safety risks due to their pure opioid activity and potential for respiratory depression, mirroring that of potent opioids.
  • The multifaceted pharmacological actions of kratom, involving opioid, serotonergic, and adrenergic systems, suggest a complex mechanism for its reported benefits in pain relief and mood elevation, contrasting with the targeted approach of conventional pharmaceuticals.
  • The dealkalinated extract of the coca leaf, stripped of its alkaloids, is still used as a flavoring agent in Coca-Cola and Coke Zero, contributing to their unique taste.
  • The speaker’s career trajectory was significantly influenced by a pivotal summer research program in medicinal chemistry and a persuasive department chair, leading them from pharmacy to graduate studies and a career in research and education.
  • The speaker’s research journey has spanned various natural products, including lobeline, nicotine analogs, salvinorin A from Salvia divinorum, and most recently, mitragynine from Mitragyna speciosa (Kratom), driven by a passion for understanding plant-derived compounds and their medicinal potential.

Segments

U.S. Kratom Products vs. Traditional (00:10:59)
  • Key Takeaway: Kratom products in the U.S. are often concentrated extracts or isolates, fundamentally different from the whole leaf used traditionally, leading to vastly different pharmacokinetic profiles and potential risks.
  • Summary: The conversation delves into the significant differences between traditional kratom use (fresh leaves, decoctions) and U.S. products (dried leaves, powders, extracts, isolates). The analogy of comparing light beer to pure alcohol is used to illustrate the spectrum of concentration and potential impact.
Kratom User Motivations and Risks (00:24:23)
  • Key Takeaway: While many U.S. kratom users seek energy, mood elevation, or pain relief, a concerning subset uses highly concentrated or derived products for opioid-like effects, and the lack of clear labeling contributes to accidental overconsumption.
  • Summary: The discussion explores the diverse reasons people use kratom, including energy, mood, pain management, and as an alternative to opioids. It highlights the surprising finding that most surveyed users are not seeking a ‘high’ but rather functional benefits, while also acknowledging the risks associated with concentrated products and the potential for physical dependence.
Alkaloids and Natural Product Medicine (00:37:41)
  • Key Takeaway: Kratom, like many medicinal plants, contains numerous alkaloids, which are organic molecules with nitrogen that interact with the body’s proteins, forming the basis for many natural product-derived medicines.
  • Summary: Dr. McCurdy explains what alkaloids are, providing examples like caffeine, cocaine, and morphine. The conversation touches on how the nitrogen in alkaloids facilitates interactions with biological targets, and how many modern pharmaceuticals originate from natural products, drawing parallels to the historical use of plants and animals in medicine.
Kratom’s Complex Pharmacology (01:05:20)
  • Key Takeaway: Kratom’s diverse alkaloids target multiple bodily systems, differentiating it from single-target opioids and highlighting the need to distinguish between leaf products and potent isolates.
  • Summary: The discussion delves into kratom’s ‘pharmaceutical shotgun’ nature, explaining how its various alkaloids interact with different systems. It emphasizes that 7-hydroxymitragynine, a metabolite, is a pure opioid and that kratom-derived isolates mimic powerful opioids, necessitating caution with serving sizes and product types.
Age Restrictions and Developing Brains (01:09:21)
  • Key Takeaway: The developing brain, continuing to mature until the mid-20s, is particularly vulnerable to the psychoactive effects of substances like kratom, leading to recommendations for avoidance in individuals under 18, 21, or even 25.
  • Summary: The conversation addresses the question of whether individuals under 18 should avoid kratom, with the consensus leaning towards a strong ’no’ due to the ongoing development of the prefrontal cortex. The analogy to cannabis use and its impact on brain development is drawn, and the speaker expresses concern about young people experimenting with unknown kratom products.
Kratom vs. Opioids: Respiratory Depression (01:17:02)
  • Key Takeaway: While whole kratom leaf is anecdotally considered to have less respiratory depression than traditional opioids, synthetically derived 7-hydroxymitragynine products have demonstrated equivalent respiratory depression in animal studies, raising significant safety concerns.
  • Summary: The discussion explores the potential for kratom to cause respiratory suppression, referencing an upcoming paper. It highlights that while whole kratom is believed to be less risky in this regard, the isolated 7-hydroxymitragynine metabolite, when synthesized, shows opioid-like respiratory depression in rats, which is reversible with naloxone.
Plant Chemistry and Natural Products (01:30:05)
  • Key Takeaway: Kratom’s therapeutic potential, particularly for pain relief and mood elevation, arises from a complex interplay of alkaloids targeting opioid, serotonergic, and adrenergic systems simultaneously, a multi-target approach that contrasts with the single-target focus of medicinal chemistry.
  • Summary: The conversation shifts to the intricate chemical composition of the kratom plant, explaining that while mitragynine is the major alkaloid, other compounds significantly influence its effects on mood, pain, and stimulation. The speaker emphasizes that the plant’s benefit may stem from this synergistic action across multiple neurotransmitter systems, a concept that challenges the reductionist approach in drug development.
Coca Leaf in Coca-Cola (02:13:42)
  • Key Takeaway: The dealkalinated extract of the coca leaf, devoid of psychoactive alkaloids, remains a crucial flavoring component in Coca-Cola and Coke Zero, contributing to their signature taste.
  • Summary: This segment details the continued use of coca leaf extract in Coca-Cola products after the cocaine has been removed. It explains how this extract is considered ‘generally recognized as safe’ (GRAS) and is the secret ingredient for Coca-Cola’s unique flavor. The discussion also touches upon Coca-Cola’s attempt to distance itself from the cocaine industry in the 1980s with ‘New Coke’ and how the original flavor profile, reliant on the coca extract, led to its return.
Speaker’s Career Path (02:20:21)
  • Key Takeaway: A pivotal summer research experience in medicinal chemistry, encouraged by a professor, redirected the speaker from a planned pharmacy career to graduate studies and a career in scientific research and education.
  • Summary: The speaker recounts their early life influences, including a pharmacist father and an educator mother, and their initial path towards pharmacy school. A key turning point was an invitation to work in a medicinal chemistry lab during pharmacy school, which led to a summer research program that ultimately convinced them to pursue a PhD in medicinal chemistry instead of practicing pharmacy.
Research on Natural Products (02:28:07)
  • Key Takeaway: The speaker’s research has focused on natural products with potential therapeutic applications, including lobeline for Alzheimer’s, nicotine analogs for neuroprotection, and salvonorin A from Salvia divinorum for its potent hallucinogenic properties.
  • Summary: This segment delves into the speaker’s doctoral and postdoctoral research, starting with the synthesis of lobeline analogs for potential Alzheimer’s treatment, inspired by early findings on nicotine’s effects. It then moves to their work on Salvia divinorum and its compound salvonorin A, highlighting its interaction with kappa opioid receptors and its unique chemical structure.
Kratom Research and Nuance (02:34:27)
  • Key Takeaway: Mitragyna speciosa (Kratom) has a complex profile with potential analgesic and antitussive properties, but its development was halted due to comparable efficacy to codeine and the emergence of safer NSAIDs, necessitating careful consideration of its use and risks.
  • Summary: The conversation shifts to Kratom, with the speaker explaining how their research on Salvia divinorum led them to study Mitragyna speciosa. They discuss the historical research by SmithKline and French on mitragynine, its comparable effects to codeine, and why it wasn’t fully developed. The segment emphasizes the importance of understanding the nuances of Kratom, including serving size, intended use, and potential drug interactions, rather than viewing it as simply ‘good’ or ‘bad’.